I-MAB American Depositary Shares
Symbol: IMAB (NASDAQ)
5.08
▼ (-2.78%) -0.145
Company Description:
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Key Stats
- Today's Open: $5.1
- Today's High: $5.12
- Today's Low: $5.075
- Today's Volume: 321
- Yesterday Close: $5.22
- Yesterday High: $5.97
- Yesterday Low: $5.0604
- Yesterday Volume: 2.04M
- Last Min Volume: 209
- Last Min High: $5.113
- Last Min Low: $5.075
- Last Min VWAP: $5.113
Company Profile
- Name: I-MAB American Depositary Shares
- Website: https://www.i-mabbiopharma.com
- Listed Date: 2020-01-17
- Location: ,
- Market Status: Active
- CIK Number: 0001778016
- SIC Code:
- SIC description:
- Market Cap: $601.69M
- Round Lot: 100
- Outstanding Shares: 115.27M
- Asset Type: ADRC
RECENT FILINGS FOR IMAB
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-16 | 6-K | View |
| 2025-10-06 | 6-K | View |
| 2025-09-24 | 6-K | View |
| 2025-09-11 | S-8 | View |
| 2025-09-08 | 6-K | View |
| 2025-08-25 | 6-K | View |
| 2025-08-20 | 6-K | View |
| 2025-08-11 | 6-K | View |
| 2025-08-07 | SCHEDULE 13D/A | View |
| 2025-08-05 | SCHEDULE 13D | View |
| 2025-08-04 | 424B5 | View |
| 2025-08-04 | 6-K | View |
| 2025-08-01 | 6-K | View |
| 2025-08-01 | F-6EF | View |
| 2025-07-17 | 6-K | View |
| 2025-07-11 | 6-K | View |
| 2025-07-11 | 424B5 | View |
| 2025-07-11 | 6-K/A | View |
| 2025-07-02 | 6-K | View |
| 2025-06-26 | 6-K | View |
Latest News on IMAB